Tag: Complement inhibitors

Approximately 85% of generalized myasthenia gravis cases are driven by an immune system attack, highlighting the role of complement inhibitors like Eculizumab and avacopan. What is the difference between Eculizumab and avacopan, and how do their targeted actions impact treatment for various autoimmune conditions?

According to the ADVOCATE clinical trial, avacopan (brand name Tavneos) led to significantly higher rates of sustained remission at 52 weeks compared to a prednisone-tapering regimen for patients with ANCA-associated vasculitis. Understanding **what does avacopan do** is crucial for patients and healthcare providers exploring this targeted treatment option.